Sandy Srinivas, MD, identifies the unmet needs for patients with renal cell carcinoma and cites the importance of the KEYNOTE-564 trial, which is looking at the role of immunotherapy with pembrolizumab in patients with high-risk disease who have undergone a nephrectomy. Dr Srinivas notes that while we await final data on overall survival for this trial, it is an important step in identifying "the right therapy for the right patient."
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Unmet Needs in the Era of Precision Medicine for RCC - Medscape - Jan 20, 2022.